BRAF and melanoma: For example, melanomas associated with the oncogenic BRAF V600E mutation may become resistant to the V600E-specific drug vemurafenib by taking advantage of an alternative splicing event that removes the V600E-containing domain, which otherwise would have promoted aberrant signaling through the MAPK pathway [19].